Understanding the utility of adjuvant systemic therapy for primary breast cancer - PubMed (original) (raw)
Understanding the utility of adjuvant systemic therapy for primary breast cancer
C L Loprinzi et al. J Clin Oncol. 2001.
Abstract
Purpose: Physicians and patients require quantitative information on the expected benefits of adjuvant therapy for primary breast cancer to make appropriate treatment decisions. To date, there has not been any widely available method for estimating the benefits from adjuvant systemic therapy, in terms of long-term disease-free survival probabilities, in patients with primary breast cancer.
Methods: Baseline prognostic information for primary breast cancer patients was estimated by asking 11 breast cancer specialists to complete a questionnaire on baseline prognosis and then using mean values. Data on the relative benefits of adjuvant therapy were culled from systematic reviews and randomized controlled trials. A computer algorithm was developed to calculate 10-year absolute outcome data. Results from this evaluation were compared with a previously described actuarial algorithm.
Results: Individual prognostic estimates varied within a group of breast cancer specialists, but mean values of their estimates closely followed published data. Translation of expected benefits of adjuvant therapy from relative to absolute terms was performed with a simple computer algorithm. The data were translated into tabular forms to facilitate user-friendly clinical use.
Conclusion: The provided data should facilitate a better understanding of the absolute magnitude of benefit for available systemic adjuvant therapies in individual women with primary breast cancer. This should allow patients to make more informed decisions about their options.
Comment in
- Assessing adjuvant breast cancer therapy benefit.
Sleeper AM. Sleeper AM. J Clin Oncol. 2001 Jun 15;19(12):3157-8; author reply 3158-9. doi: 10.1200/JCO.2001.19.12.3157. J Clin Oncol. 2001. PMID: 11408515 No abstract available. - Assessing adjuvant breast cancer therapy benefit.
Sorscher SM, Dietrich LL. Sorscher SM, et al. J Clin Oncol. 2001 Jun 15;19(12):3158-9. J Clin Oncol. 2001. PMID: 11417570 No abstract available.
Similar articles
- Estimating the benefits of adjuvant systemic therapy for women with early breast cancer.
Grogan M, Tabar L, Chua B, Chen HH, Boyages J. Grogan M, et al. Br J Surg. 2001 Nov;88(11):1513-8. doi: 10.1046/j.0007-1323.2001.01902.x. Br J Surg. 2001. PMID: 11683751 Clinical Trial. - Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Ravdin PM, et al. J Clin Oncol. 2001 Feb 15;19(4):980-91. doi: 10.1200/JCO.2001.19.4.980. J Clin Oncol. 2001. PMID: 11181660 - Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M. Ragaz J, et al. J Natl Cancer Inst. 2005 Jan 19;97(2):116-26. doi: 10.1093/jnci/djh297. J Natl Cancer Inst. 2005. PMID: 15657341 Clinical Trial. - Adjuvant therapy for breast cancer.
[No authors listed] [No authors listed] NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. NIH Consens Statement. 2000. PMID: 11512506 Review. - Adjuvant chemotherapy in early breast cancer.
Ejlertsen B. Ejlertsen B. Dan Med J. 2016 May;63(5):B5222. Dan Med J. 2016. PMID: 27127018 Review.
Cited by
- Assessment of Machine Learning to Estimate the Individual Treatment Effect of Corticosteroids in Septic Shock.
Pirracchio R, Hubbard A, Sprung CL, Chevret S, Annane D; Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis (RECORDS) Collaborators. Pirracchio R, et al. JAMA Netw Open. 2020 Dec 1;3(12):e2029050. doi: 10.1001/jamanetworkopen.2020.29050. JAMA Netw Open. 2020. PMID: 33301017 Free PMC article. - Management of hormone receptor-positive, HER2-negative early breast cancer.
Walsh EM, Smith KL, Stearns V. Walsh EM, et al. Semin Oncol. 2020 Aug;47(4):187-200. doi: 10.1053/j.seminoncol.2020.05.010. Epub 2020 Jun 3. Semin Oncol. 2020. PMID: 32546323 Free PMC article. Review. - Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Rivera DR, et al. J Natl Cancer Inst. 2018 Feb 1;110(2):djx140. doi: 10.1093/jnci/djx140. J Natl Cancer Inst. 2018. PMID: 28954296 Free PMC article. Review. - Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
Wazir U, Mokbel K, Carmichael A, Mokbel K. Wazir U, et al. Cell Mol Biol Lett. 2017 Sep 4;22:20. doi: 10.1186/s11658-017-0049-x. eCollection 2017. Cell Mol Biol Lett. 2017. PMID: 28878809 Free PMC article. Review. - Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Stavridi F, Kalogeras KT, Pliarchopoulou K, Wirtz RM, Alexopoulou Z, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Stavridi F, et al. PLoS One. 2016 Oct 3;11(10):e0164013. doi: 10.1371/journal.pone.0164013. eCollection 2016. PLoS One. 2016. PMID: 27695115 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical